French Biotech Valneva Updates Global Investors on Latest Developments
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Valneva SE filed a Form 6-K report on June 28, 2025, indicating the issuance of a press release dated June 26, 2025. The filing was signed by CEO and President Thomas Lingelbach.
This Form 6-K submission serves primarily as a notification of foreign issuer disclosure, with the company confirming it files annual reports under Form 20-F. The press release content (Exhibit 99.1) is referenced but not detailed in the main filing.
Notably, the information contained in this Form 6-K, including Exhibit 99.1, has been incorporated by reference into the company's Registration Statement on Form F-3 (File No. 333-286071), which could indicate potential future securities offerings or other significant corporate actions.
Positive
- None.
Negative
- None.
FAQ
What type of SEC filing did VALN submit on June 28, 2025?
VALN submitted a Form 6-K (Report of Foreign Private Issuer) on June 28, 2025. The filing includes a press release dated June 26, 2025, which was incorporated by reference into the company's Registration Statement on Form F-3.
Who is the current CEO of Valneva SE (VALN)?
Thomas Lingelbach is the Chief Executive Officer and President of Valneva SE, as confirmed by his signature on the Form 6-K dated June 26, 2025.
Where is VALN's principal executive office located?
Valneva SE's principal executive office is located at 6 rue Alain Bombard, 44800 Saint-Herblain, France.
What type of annual reports does VALN file with the SEC?
According to the Form 6-K, Valneva SE files annual reports under Form 20-F, as indicated by the checked box in the filing.
What registration statement is this VALN Form 6-K incorporated into?
The Form 6-K and its Exhibit 99.1 are incorporated by reference into Valneva SE's Registration Statement on Form F-3 (File No. 333-286071).